Porth's Essentials of Pathophysiology, 4e

128

Cell and Tissue Function

U N I T 1

30. Roizen NJ, Patterson D. Down syndrome. Lancet. 2003;361: 1281–1289. 31. Weijerman ME, de Winter JP. The care of children with Down syndrome. Eur J Pediatr. 2010;169:1445–1452. 32. Wiseman FK, Afford KA, Tylbulewica VLJ, et al. Down syndrome—recent progress and future prospects. Hum Mol Genet. 2009;18:E75–E83. 33. Rappaport VJ. Prenatal diagnosis and genetic screening— integration into prenatal care. Obstet Gynecol Clin North Am. 2008;35:435–458. 34. Sybert VP, McCauley E. Turner’s syndrome. N Engl J Med. 2004;351:1227–1238. 35. Morgan T. Turner syndrome: diagnosis and management. Am Fam Physician. 2007;76:405–410. 36. Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol. 2004;151:657–687. 37. Elsheikh M, Dunger DB, Conway GS, et al. Turner syndrome in adulthood. Endocr Rev. 2002;21:120–140. 38. Frías JL, Davenport ML, American Academy of Pediatrics Committee on Genetics, Section on Endocrinology. Health supervision of children with Turner syndrome. Pediatrics. 2005;111:692–702. 39. Chacko E, Regelmann MO, Costin G. Updates on Turner and Noonan syndromes. Endocrinol Metab Clin North Am. 2012;41:713–734. 40. Gonxalez L, Witchel SF. The patient with Turner syndrome: puberty and medical management concerns. Fertil Steril. 2012;98(4):780–786. 41. Davenport ML. Approach to patient with Turner syndrome. J Clin Endocrinol Metab. 2010;95(4):1487–1495. 42. Pinsker JE. Turner syndrome: updating the paradigm of clinical care. J Clin Endocrinol Metab. 2012;97(6):E994–E1003. 43. National Institutes of Health. Understanding Klinefelter Syndrome . 2013. Available at: http://ghr.nlm.nih.gov/condition/ klinefelter-syndrome. Accessed October 11, 2013. 44. Lanfranco F, Kamischke A, Zitzmann M, et al. Klinefelter syndrome. Lancet. 2004;364:273–283. 45. Wattendorf DJ, Muenke M. Klinefelter syndrome. Am Fam Physician. 2005;72(11):2259–2262. 46. Wikström A, Dunkel L. Klinefelter syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(2):239–250. 47. Groth KA, Skakkebaek A, Høst C, et al. Klinefelter syndrome—a clinical update. J Clin Endocrinol Metab. 2013;98(1):20–30. 48. Brent RL. Environmental causes of congenital malformations: the pediatrician’s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics. 2004;113:957–968. 49. Steurerwald U, Weibe P, Jorgensen PJ, et al. Maternal seafood diet, methylmercury exposure, and neonatal neurologic function. J Pediatr. 2000;136:599–605. 50. Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology . 12th ed. New York, NY: McGraw-Hill Medical; 2013:1039–1043.

51. Ross SA, McCaffery PJ, Drager UC, et al. Retinoids in embryonal development. Physiol Rev. 2000;80:1021–1055. 52. Bertrand J, Floyd RL, Weber MK, et al.; for the National Task Force on Fetal Alcohol and Fetal Alcohol Effects. Fetal Alcohol Syndromes: Guidelines for Referral and Diagnosis . Atlanta, GA: Centers for Disease Control and Prevention; 2004. 53. Sokol RJ, Delaney-Black V, Nordstrom B. Fetal alcohol syndrome. JAMA. 2003;290(22):2996–2999. 54. Wattendorf DJ, Muenke M. Fetal alcohol spectrum disorders. Am Fam Physician. 2005;72(2):279–285. 55. Riley EP, McGee CL. Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior. Exp Biol Med. 2005;230(6):357–365. 56. Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum disorders: an overview. Neuropsychol Rev. 2011;21(3):75–80. 57. Centers for Disease Control and Prevention. Recommendations for use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992;41:1–8. 58. Bailey LB. New standard for dietary folate intake in pregnant women. Am J Clin Nutr. 2000;71(Suppl):1304S–1307S. 59. Jones J, Lopez A, Wilson M. Congenital toxoplasmosis. Am Fam Physician. 2003;67:2131–2138. 60. Kirkham C, Harris S, Grzybowski S. Evidence-based prenatal care: part I. General prenatal care and counseling issues. Am Fam Physician. 2005;71(7):1307–1316. 61. Graves JC, Miller KE. Maternal serum triple analyte screening in pregnancy. Am Fam Physician. 2002;65(5):915–920. 62. Qin Q-P, Christiansen M, Pettersson K. Point of care time- resolved immunofluorometric assay of human pregnancy- associated plasma protein A: use in first-trimester screening for Down syndrome. Clin Chem. 2002;48(3):473–483. 63. Lambert-Messerlian GM, Canick JA. Clinical application of inhibin A measurement: prenatal serum screening for Down syndrome. Semin Reprod Med. 2004;22(3):235–242. 64. Ashoor G, Syngelaki A, Poon LCY, et al. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41:26–32. 65. Wilson RD. Amniocentesis and chorionic villus sampling. Curr Opin Obstet Gynecol. 2000;12:81–86.

Porth Essentials Resources Explore these additional resources to enhance learning for this chapter: •  NCLEX-Style Questions and Other Resources

on

, http://thePoint.lww.com/PorthEssentials4e

• Study Guide for Essentials of Pathophysiology • Adaptive Learning | Powered by PrepU, http://thepoint.lww.com/ prepu

Made with